Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
Repository logoRepository logo
  • Communities & Collections
  • All Contents
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Sahin A."

Now showing 1 - 6 of 6
Results Per Page
Sort Options
  • No Thumbnail Available
    Item
    Karyological studies on eight species of Onobrychis genus in Turkey
    (2011) Sepet H.; Emre I.; Kiran Y.; Kursat M.; Sahin A.
    This study used karyological techniques to determine the chromosome numbers and morphology of eight species of Onobrychis L. (O. caput-galli (L.) Lam, O. aequidentata (Sibth. & Sm.) d' Urv, O. fallax Freyn & Sint. var. fallax, O. lasiostachya Boiss, O. viciifolia Scop., O. oxyodonta Boiss. subsp. armena (Bois. & Huet) Aktoklu, O. hypargyrea Boiss. and O. cappadocica Boiss.). The results of this study determined the chromosome numbers of O. cappadocica as 2n = 16; O. viciifolia as 2n = 28 and the other species as 2n = 14 The karyotypes of species consisted of median-centromeric (m) or submedian-centromeric (sm) chromosomes. However, O. oxyodonta Boiss. subsp. armena (Bois. & Huet) Aktoklu was found to have only the median-centromeric (m) chromosomes. According to the results of the present study, of the eight Onobrychis taxa, only O. hypargyrea has a pair of satellite chromosomes (sat-chromosome). Furthermore, this study detected karyotype asymmetry. © 2011 Versita Warsaw and Springer-Verlag Wien.
  • No Thumbnail Available
    Item
    A review of suspected cases of driving under the influence of drugs (DUID) involved in traffic accidents in Istanbul (Turkey)
    (Churchill Livingstone, 2013) Acar F.; Asirdizer M.; Aker R.G.; Kucukibrahimoglu E.E.; Ates I.; Erol Y.; Sahin A.
    Nowadays traffic accidents, which have high mortality and morbidity, are an important public health problem. The association between the use of alcohol and/or drugs by drivers and the increased risk of traffic accidents with a high risk of death and injury has been well described in the literature. This study aimed to review the incidence of cases of driving under the influence of drugs (DUID) among all cases of driving under the influence (DUI) of alcohol and/or other drugs involved in traffic accidents and to evaluate the type of the psychoactive drugs (with or without alcohol) detected in blood samples in Istanbul and its surrounding area. This study is the first investigation on the subject of DUID cases in Turkey. The reports of the Istanbul Toxicology Department of the Council of Forensic Medicine (Turkey) on suspected DUID cases involved in traffic accidents between 1 July 2010 and 30 June 2011 were retrospectively reviewed for alcohol and/or drug use. Alcohol analysis was requested in 4274 suspected DUI cases, whereas drug along with alcohol analysis was requested in only 91. The rate of suspected DUID cases (n = 91) among the suspected DUI cases (n = 4274) was only 2.1% and in this study, we evaluated only the DUID cases in detail. Alcohol was present in 44% of suspected DUID cases. Psychoactive drugs were present in 15.4% of cases. The incidence among 46 confirmed DUID cases was found to be 17.4% for cannabis, 8.7% for benzodiazepines, 4.3% for barbiturates, 4.3% for antidepressants, 2.2% for cocaine and 2.2% for amphetamines. Although there is a zero-tolerance approach for DUID in the Turkish regulations, it is not well recognised and not inspected by police and legal authorities who are responsible for taking measures in traffic accidents and for routine traffic controls in Turkey. It is concluded that psychoactive drugs should be checked as well as alcohol in all traffic accident cases and roadside controls. © 2013 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.
  • No Thumbnail Available
    Item
    The effect of mad honey on testosterone levels of male rats
    (Comenius University, 2016) Tatli O.; Karaca Y.; Turkmen S.; Gulgen G.S.; Sahin A.; Eryigit U.; Fazli O.; Karaguzel E.; Mentese A.; Orem A.; Cansu A.; Turedi S.; Gunduz A.
    OBJECTIVE: We aimed to investigate the effect of mad honey on sexual performance. BACKGROUND: In traditional medicine in Turkey, mad honey is used to improve appetite, to heighten mental alertness, to reduce joint pain, to eliminate gastrointestinal system pains and to increase sexual performance. METHODS: In this experimental animal study eighteen Sprague Dawley male rats were randomized into three groups, a control group, a normal honey group and a mad honey group. Rats in the treatment groups were given a daily dose of 80 mg/kg normal honey or mad honey throughout the 30-day study period. Total testosterone, free testosterone, FSH, LH, estradiol, and progesterone levels were subsequently investigated from blood sera on day 30. RESULTS: Comparison of blood total testosterone levels among the groups revealed significantly higher levels in the mad honey group compared to the normal honey and control groups (p = 0.006, p = 0.00). Free testosterone levels were also significantly higher in the mad honey group than in the normal honey and control groups (p = 0.023, p = 0.01). No statistically significant differences were determined for other hormonal measurements. CONCLUSIONS: This study revealed a significant increase in both total and free testosterone levels in mad- -honey group.
  • No Thumbnail Available
    Item
    Epidemiological, Clinical, and Laboratory Features of Children With COVID-19 in Turkey
    (Frontiers Media S.A., 2021) Karbuz A.; Akkoc G.; Bedir Demirdag T.; Yilmaz Ciftdogan D.; Ozer A.; Cakir D.; Hancerli Torun S.; Kepenekli E.; Erat T.; Dalgic N.; Ilbay S.; Karaaslan A.; Erdeniz E.H.; Aygun F.D.; Bozdemir S.E.; Hatipoglu N.; Emiroglu M.; Sahbudak Bal Z.; Ciftci E.; Bayhan G.I.; Gayretli Aydin Z.G.; Ocal Demir S.; Kilic O.; Hacimustafaoglu M.; Sener Okur D.; Sen S.; Yahsi A.; Akturk H.; Cetin B.; Sutcu M.; Kara M.; Uygun H.; Tural Kara T.; Korukluoglu G.; Akgun O.; Üstündağ G.; Demir Mis M.; Sali E.; Kaba O.; Yakut N.; Kılıc O.; Kanik M.K.; Cetin C.; Dursun A.; Cicek M.; Kockuzu E.; Sevketoglu E.; Alkan G.; Guner Ozenen G.; İnce E.; Baydar Z.; Ozkaya A.K.; Ovali H.F.; Tekeli S.; Celebi S.; Cubukcu B.; Bal A.; Khalilova F.; Kose M.; Hatipoglu H.U.; Dalkiran T.; Turgut M.; Basak Altas A.; Selcuk Duru H.N.; Aksay A.; Saglam S.; Sari Yanartas M.; Ergenc Z.; Akin Y.; Duzenli Kar Y.; Sahin S.; Tuteroz S.K.; Bilen N.M.; Ozdemir H.; Senoglu M.C.; Pariltan Kucukalioglu B.; Besli G.E.; Kara Y.; Turan C.; Selbest Demirtas B.; Celikyurt A.; Cosgun Y.; Elevli M.; Sahin A.; Bahtiyar Oguz S.; Somer A.; Karadag B.; Demirhan R.; Turk Dagi H.; Kurugol Z.; Taskin E.C.; Sahiner A.; Yesil E.; Ekemen Keles Y.; Sarikaya R.; Erdem Eralp E.; Ozkinay F.; Konca H.K.; Yilmaz S.; Gokdemir Y.; Arga G.; Ozen S.; Coksuer F.; Vatansever G.; Tezer H.; Kara A.
    Objectives: The aim of this study is to identify the epidemiological, clinical, and laboratory features of coronavirus disease 2019 (COVID-19) in children. Methods: A retrospective study was conducted by pediatric infectious disease specialists from 32 different hospitals from all over Turkey by case record forms. Pediatric cases who were diagnosed as COVID-19 between March 16, 2020, and June 15, 2020 were included. Case characteristics including age, sex, dates of disease onset and diagnosis, family, and contact information were recorded. Clinical data, including the duration and severity of symptoms, were also collected. Laboratory parameters like biochemical tests and complete blood count, chest X-ray, and chest computed tomography (CT) were determined. Results: There were 1,156 confirmed pediatric COVID-19 cases. In total, male cases constituted 50.3% (n = 582) and females constituted 49.7% (n = 574). The median age of the confirmed cases was 10.75 years (4.5–14.6). Of the total cases, 90 were younger than 1 year of age (7.8%), 108 were 1–3 years of age (9.3%), 148 were 3–6 years of age (12.8%), 298 were 6–12 years of age (25.8%), 233 were 12–15 years of age (20.2%), and 268 cases were older than 15 years of age (23.2%). The most common symptom of the patients at the first visit was fever (50.4%) (n = 583) for a median of 2 days (IQR: 1–3 days). Fever was median at 38.4°C (38.0–38.7°C). The second most common symptom was cough (n = 543, 46.9%). The other common symptoms were sore throat (n = 143, 12.4%), myalgia (n = 141, 12.2%), dyspnea (n = 118, 10.2%), diarrhea (n = 112, 9.7%), stomachache (n = 71, 6.1%), and nasal discharge (n = 63, 5.4%). When patients were classified according to disease severity, 263 (22.7%) patients were asymptomatic, 668 (57.7%) patients had mild disease, 209 (18.1%) had moderate disease, and 16 (1.5%) cases had severe disease. One hundred and forty-nine (12.9%) cases had underlying diseases among the total cases; 56% of the patients who had severe disease had an underlying condition (p < 0.01). The need for hospitalization did not differ between patients who had an underlying condition and those who do not have (p = 0.38), but the need for intensive care was higher in patients who had an underlying condition (p < 0.01). Forty-seven (31.5%) of the cases having underlying conditions had asthma or lung disease (38 of them had asthma). Conclusions: To the best of our knowledge, this is one of the largest pediatric data about confirmed COVID-19 cases. Children from all ages appear to be susceptible to COVID-19, and there is a significant difference in symptomatology and laboratory findings by means of age distribution. © Copyright © 2021 Karbuz.
  • No Thumbnail Available
    Item
    Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome
    (Frontiers Media S.A., 2022) Vitale A.; Caggiano V.; Della Casa F.; Hernández-Rodríguez J.; Frassi M.; Monti S.; Tufan A.; Telesca S.; Conticini E.; Ragab G.; Lopalco G.; Almaghlouth I.; Pereira R.M.R.; Yildirim D.; Cattalini M.; Marino A.; Giani T.; La Torre F.; Ruscitti P.; Aragona E.; Wiesik-Szewczyk E.; Del Giudice E.; Sfikakis P.P.; Govoni M.; Emmi G.; Maggio M.C.; Giacomelli R.; Ciccia F.; Conti G.; Ait-Idir D.; Lomater C.; Sabato V.; Piga M.; Sahin A.; Opris-Belinski D.; Ionescu R.; Bartoloni E.; Franceschini F.; Parronchi P.; de Paulis A.; Espinosa G.; Maier A.; Sebastiani G.D.; Insalaco A.; Shahram F.; Sfriso P.; Minoia F.; Alessio M.; Makowska J.; Hatemi G.; Akkoç N.; Li Gobbi F.; Gidaro A.; Olivieri A.N.; Al-Mayouf S.M.; Erten S.; Gentileschi S.; Vasi I.; Tarsia M.; Mahmoud A.A.-M.A.; Frediani B.; Fares Alzahrani M.; Laymouna A.H.; Ricci F.; Cardinale F.; Jahnz-Rózyk K.; Tosi G.M.; Crisafulli F.; Balistreri A.; Dagostin M.A.; Ghanema M.; Gaggiano C.; Sota J.; Di Cola I.; Fabiani C.; Giardini H.A.M.; Renieri A.; Fabbiani A.; Carrer A.; Bocchia M.; Caroni F.; Rigante D.; Cantarini L.
    Objective: The aim of this paper is to present the AutoInflammatory Disease Alliance (AIDA) international Registry dedicated to Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome, describing its design, construction, and modalities of dissemination. Methods: This Registry is a clinical, physician-driven, population- and electronic-based instrument designed for the retrospective and prospective collection of real-life data. Data gathering is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain real-world evidence for daily patients' management. The Registry may potentially communicate with other on-line tools dedicated to VEXAS syndrome, thus enhancing international collaboration and data sharing for research purposes. The Registry is practical enough to be easily modified to meet future needs regarding VEXAS syndrome. Results: To date (April 22nd, 2022), 113 Centers from 23 Countries in 4 continents have been involved; 324 users (114 Principal Investigators, 205 Site Investigators, 2 Lead Investigators, and 3 data managers) are currently able to access the registry for data entry (or data sharing) and collection. The Registry includes 4,952 fields organized into 18 instruments designed to fully describe patient's details about demographics, clinical manifestations, symptoms, histologic details about skin and bone marrow biopsies and aspirate, laboratory features, complications, comorbidities, therapies, and healthcare access. Conclusion: This international Registry for patients with VEXAS syndrome will allow the achievement of a comprehensive knowledge about this new disease, with the final goal to obtain real-world evidence for daily clinical practice, especially in relation to the comprehension of this disease about the natural history and the possible therapeutic approaches. This Project can be found on https://clinicaltrials.gov NCT05200715. Copyright © 2022 Vitale, Caggiano, Della Casa, Hernández-Rodríguez, Frassi, Monti, Tufan, Telesca, Conticini, Ragab, Lopalco, Almaghlouth, Pereira, Yildirim, Cattalini, Marino, Giani, La Torre, Ruscitti, Aragona, Wiesik-Szewczyk, Del Giudice, Sfikakis, Govoni, Emmi, Maggio, Giacomelli, Ciccia, Conti, Ait-Idir, Lomater, Sabato, Piga, Sahin, Opris-Belinski, Ionescu, Bartoloni, Franceschini, Parronchi, de Paulis, Espinosa, Maier, Sebastiani, Insalaco, Shahram, Sfriso, Minoia, Alessio, Makowska, Hatemi, Akkoç, Li Gobbi, Gidaro, Olivieri, Al-Mayouf, Erten, Gentileschi, Vasi, Tarsia, Mahmoud, Frediani, Fares Alzahrani, Laymouna, Ricci, Cardinale, Jahnz-Rózyk, Tosi, Crisafulli, Balistreri, Dagostin, Ghanema, Gaggiano, Sota, Di Cola, Fabiani, Giardini, Renieri, Fabbiani, Carrer, Bocchia, Caroni, Rigante and Cantarini.
  • No Thumbnail Available
    Item
    The REM-sleep-related characteristics of narcolepsy: a nation-wide multicenter study in Turkey, the REMCON study
    (Elsevier B.V., 2022) Akyildiz U.O.; Tezer F.I.; Koc G.; Ismailogullari S.; Demir A.B.; Ak A.K.; Sunter G.; Kara K.A.; Berktas D.T.; Sahin A.; Azman F.; Akcay B.D.; Gok D.K.; Yilmaz H.; Agan K.; Bekmezci Y.; Yetkin S.; Aksu M.; Karadeniz D.; Senel G.B.
    Introduction: Narcolepsy type 1 (NT1) is caused by hypocretin deficiency, the pathophysiology of narcolepsy type 2 (NT2) has not been delineated. Except for the hypocretin deficiency and cataplexy, all clinical and laboratory features used in the diagnosis of NT2 are identical to those used for NT1. The aim of this study was to assess the rapid eye movement (REM) sleep-related characteristics in the patients with narcolepsy; the characteristics of REM sleep in polysomnography (PSG) and multiple sleep latency test (MSLT) recordings, the quantification of REM sleep without atonia (RSWA) and atonia index, and the analysis of rapid eye movements (REMs) during REM sleep. Materials and methods: This study was planned by the Sleep Medicine Study Group of the Turkish Neurology Society, and conducted in 11 centers in eight cities in Turkey. The analysis of RSWA was analyzed by reviewing all REM sleep periods on nocturnal PSG and MSLT recordings per standard criteria. The total duration of the increased muscle tone during REM sleep in the chin and bilateral leg electromyography (EMG) recordings was calculated as RSWA index. The REMs index was also investigated the relation to the RSWA. Results: A total of 274 patients were involved; 147 patients (53.6%) were males and 127 patients (46.4%) were females; the mean age was 29.1 ± 12.0 years. The diagnosis of NT1 was made in 166 patients (60.6%), and 108 patients (39.4%) were diagnosed as having NT2. The mean Epworth sleepiness scale score was significantly higher in patients with NT1 than the patients with NT2 (P = 0.001). The diagnosis of REM sleep behavior disorder (RBD) was made in 19.3% of the patients with NT1 versus in 2.8% of the patients with NT2 (P < 0.001). The percentage of SOREMP in PSG recordings was significantly higher in patients with NT1 (37.1%) than those with NT2 (18.9%, P = 0.001). MSLT showed that the mean sleep latency was shorter in patients with NT1 compared to those with NT2 (P < 0.001). The total duration of REMs on electrooculography recordings was also significantly higher in patients with RSWA in comparison with the patients without RSWA (P = 0.002). Total duration of REMs was significantly and positively correlated with the duration of RSWA on chin-EMG and leg-EMG recordings (P = 0.001). ROC analyses showed an RSWA index of ≥2% for the RSWA on chin-EMG with a sensitivity of 86.7% and a specificity of 71.3% (P < 0.001). The REMs index ≥20% was associated with the presence of RSWA with a sensitivity of 70.0% and a specificity of 57.1% (P = 0.008). Conclusions: In this nation-wide study, we identified for the first time that the increase in REMs density during REM sleep may be a major correlate of the RSWA. Significant positive correlations were demonstrated between the total duration of REMs on electrooculography recordings and the mean durations of RSWA in both chin and leg EMG recordings. A REMs index of >20% was demonstrated to have a moderate sensitivity and specificity in the diagnosis of RSWA. As observed in chin RSWA index, REMs index also showed a significantly high association with RBD, in comparison to RSWA per standard criteria. © 2022 Elsevier B.V.

Manisa Celal Bayar University copyright © 2002-2025 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback